Hepatocellular carcinoma (HCC) has been recognized since antiquity as one of the most lethal malignancies, yet early detection remains frustratingly elusive despite advances in imaging and serology. This research evaluated the diagnostic performance of a combined serum biomarker panel comprising alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), AFP-L3 fraction, and glypican-3 (GPC3) for early-stage HCC detection in a prospective cohort of 232 patients with chronic liver disease under surveillance at the Monterrey Institute of Advanced Studies, Mexico, from January 2016 to June 2019. The research employed a two-phase design: a discovery phase (n = 89) to identify optimal biomarker cutoff values and a validation phase (n = 143) to assess diagnostic accuracy in an independent cohort. All participants underwent six-monthly ultrasound screening alongside biomarker sampling at baseline and every three months for 18 months. During the surveillance period, 48 patients (20.7%) developed biopsy-or imaging-confirmed HCC. When used individually, AFP at the conventional 20 ng/mL cutoff detected HCC with a sensitivity of 62.5% and specificity of 83.7%. DCP performed slightly better, with sensitivity of 68.8% and specificity of 87.4%. But the combined four-biomarker panel achieved markedly superior performance: sensitivity of 86.7% and specificity of 91.3%, with an area under the receiver operating characteristic curve (AUC) of 0.934 compared to 0.781 for AFP alone (p